Online inquiry

IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10451MR)

This product GTTS-WQ10451MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SOST gene. The antibody can be applied in Canine B-cell lymphoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_025237.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50964
UniProt ID Q9BQB4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10451MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ132MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ2062MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ12553MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA NV-01
GTTS-WQ1680MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACZ885
GTTS-WQ6991MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ETI-204
GTTS-WQ852MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ11026MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ9795MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JS002
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW